Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ssk1
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
SSK1 is a senescence-specific killing compound that acts as a β-galactosidase-targeted proagent. It is activated by lysosomal β-galactosidase in senescent cells and induces apoptosis specifically in these cells. SSK1 has been shown to attenuate inflammation and may be used to reduce symptoms associated with senescence-associated diseases or disorders[1][2][3].
- Other names
- SSK1SSK-1SSK 1(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-((((1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamoyl)oxy)methyl)-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate
02
Targets
GLB1 (Galactosidase Beta 1)
Beyond the preview
Go deeper on ssk1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ssk1.